Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial
Authors' conclusion
A significant effect of semaglutide versus placebo on carotid plaque inflammation could not be detected through the methodology used in this trial, likely due to minimal baseline inflammation.
Study context
- Population
- Patients with T2DM and cardiovascular disease (CVD)
- Participants
- 101 patients
- Comparison
- Once-weekly SC semaglutide 1.0 mg vs placebo
- Primary endpoint
- Change in carotid plaque inflammation (TBRmax of [18F]FDG on PET-MRI, most diseased segments)
- Follow-up
- Baseline to week 26
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Change in TBRmax · week 26
Semaglutide vs PlaceboEstimated treatment difference (95% CI)
[18F]FDG
0.033(−0.118 to 0.184)
[68Ga]DOTATATE (key secondary)
0.045(−0.314 to 0.404)
Original publication
Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial. Am Heart J. Published 7 May 2025. doi:10.
Summarised from the published abstract; every number is checked against it